DBV Technologies Stock Rises to €3.43 Despite Lowered Price Target
The stock of the French biotech company increased by 2.2% to €3.43 mid-session in a rising Parisian market. The previous day, Kempen maintained its buy recommendation while reducing its price target from €11 to €9. This movement occurred a few days after the publication of the first quarter 2026 results.
Kempen adjusted its opinion on DBV Technologies on May 4. The Dutch firm continues to recommend buying but has lowered its target from €11 to €9. Based on the current price of €3.43, the implied upside potential remains over 160%. This revision follows the quarterly publication on April 30, which reported a net loss of $47.6 million and a significant increase in R&D expenses. The biotech also confirmed two regulatory filings in 2026 for its Viaskin Peanut patch for age groups 4-7 years and 1-3 years. The financial calendar includes the mixed general meeting on June 3, 2026, followed by the half-year results on July 29.
Price Stuck Between Support at €3.34 and MM50 at €3.60
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The stock is trading in a narrow range. The price at €3.43 is just above the support at €3.34, already tested at the beginning of the month, and remains below the 50-day moving average at €3.60. The 200-day moving average at €2.79, however, confirms the underlying bullish trend, with a performance of 125.5% over the year. The RSI at 43 remains neutral and does not indicate either overselling or overbuying. Today's rebound is in the lower part of the Bollinger Bands (lower boundary at €3.30), without breaching any major technical level. The next concrete appointment is the general meeting on June 3, 2026, before the half-year results on July 29.
Perte nette trimestrielle de (33,2) millions de dollars ; trésorerie de 69,8 millions de dollars au 30/09/2025 suite à un financement partiel (125,5 M$ reçu) et un programme ATM ; dépenses opérationnelles élevées principalement en R&D (83,8 M$ sur 9 mois). Trésorerie estimée suffisante jusqu'au T3 2026 mais incertitude significative persiste.
Risks mentioned
Incertitude significative sur la continuité d'exploitation (trésorerie insuffisante pour couvrir 12 prochains mois)
Dépendance aux financements externes (PIPE, ATM et autres levées de fonds)
Accès futur aux capitaux soumis aux conditions du marché et à l'intérêt des investisseurs
Dépendance aux résultats de l'étude de phase 3 VITESSE pour accélération d'exercices de BSA et financements supplémentaires
Opportunities identified
Financement pouvant atteindre 306,9 millions de dollars via PIPE
Programme ATM pouvant générer jusqu'à 150,0 millions de dollars
Potentiel réglementaire et commercial du patch Viaskin® Peanut (BLA et lancement aux États-Unis si approuvé)
Possibilité d'exercices supplémentaires de bons de souscription si certains critères sont atteints
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
